Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial - Wikidata - wikimedia - TriplyDB

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

http://www.wikidata.org/entity/Q28211411

about

sameAs

Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease Single dose oral lumiracoxib for postoperative pain in adults Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury Selective cyclooxygenase 2 inhibitors for the treatment of rheumatological manifestations of inflammatory bowel disease Single dose oral lumiracoxib for postoperative pain Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini Review Testing cardiovascular drug safety and efficacy in randomized trials Hydrogen sulfide prodrugs-a review Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives Chemoprevention in familial adenomatous polyposis The safety of rofecoxib The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects COX-2 chronology The effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosa Peptic ulcer disease today Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen?Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk?Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations An economic model of long-term use of celecoxib in patients with osteoarthritis Building a better aspirin: gaseous solutions to a century-old problem The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib The David Y. Graham lecture: use of nonsteroidal antiinflammatory drugs in a COX-2 restricted environment Drug-induced liver injury: recent advances in diagnosis and risk assessment.Hepatotoxicity induced by coxibs: how concerned should we be?Systematic review with meta-analysis: the gastrointestinal benefits of COX-2 selective inhibitors with concomitant use of low-dose aspirin.Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes.

P2860

Q24186593-015A3A72-7E88-482D-8160-76194F322AD7 Q24193086-72974D4F-D1DA-48D9-ADED-4A7406A4E42D Q24234242-5C92F660-76EB-48DD-8006-88A3BC8A6FC5 Q24240301-82BB5BC5-B382-4007-9E5C-5664B0870418 Q24240479-C1F51B49-2D23-4332-9CD2-37F3405DA8B5 Q24242935-CAB9DF5B-54F1-4CEE-A604-D84F6817A20C Q24546221-FA7DD60F-3BA2-42F1-B277-9948016AE931 Q24615651-01EBC97B-BD72-48BF-8170-82CBC8AC05FF Q24619410-335D6366-B70B-4B27-86A6-393BE236C149 Q24634894-C8102757-F466-4C7F-8DD9-775C0651F6FA Q26849771-ACBBD749-5DAA-4DD0-A214-F5D5AD8B9160 Q26865084-21B4BE6A-4553-49C4-9221-8185EE3D905E Q27012539-CE0C6462-B5F5-4DBC-ADE6-8F263E51052E Q27023845-A46BCB5C-735E-47F3-9980-43A730A5E0DC Q28176535-7981584E-5A07-416D-9398-CC6429FBAF4A Q28177082-8C38CAF3-34EE-424D-BCCF-D388C0FF1498 Q28191924-F2963F94-ED09-42EC-A4C3-7442503F0D91 Q28192026-49C5F367-6FFA-4197-BFF3-1CC24AF62EE2 Q28192719-8834165E-2B2F-472C-81EA-0F38235A4004 Q28194351-7C93B8EE-E4D5-4557-921F-14E17F79910B Q28194844-36B90909-215A-4535-B1C3-DBF66B25E8CF Q28196511-0E4107E0-5746-40CA-9D77-8D4357E2716A Q28200403-5FCA73D5-03DE-4842-8115-9839207A2F8A Q28200569-5066F2D5-1A9E-4A31-9660-4DDE99401343 Q28200571-511F1713-5037-4D02-A137-1DEB98BAFDEF Q28200864-3EE15535-B928-4060-BCAF-EDACACA99148 Q28217400-E14863D1-2100-468F-9601-0DC27CB0468B Q28217824-AEB98073-1015-4A26-B7CB-233A453981A5 Q28218005-E2500DBD-8F2E-401A-A4CA-9A9E5ECB4749 Q28218664-0F4D76E1-617B-4CFD-99BC-49C17620CAD0 Q28219195-3665E236-8285-4B69-877E-D8A2998CE69B Q28219220-82D4DEF3-F571-41C7-B41C-EC8E88195D6A Q28219464-02C5FD44-A5CA-4A53-B2A7-D3BA5A41A423 Q28222097-16E3EF73-161D-4ED9-AC90-EA6149EE58F0 Q28222253-0DE07A8C-0C71-4923-84B8-EE638502E6E9 Q30235089-137DF6A7-3E1E-47B0-88AE-CDDD586E0CB0 Q30244369-B3698C4A-DD16-498B-8C66-BA1823C847F2 Q30248439-79F987CE-B85C-4200-8D34-713446952E25 Q30430170-5FC50E5D-AD83-43E2-ACDF-68552F605805 Q30481876-FA11FEF8-9C8B-4BDB-A398-77954BA065E8

P2860

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

http://www.wikidata.org/entity/Q28211411

description

2004 nî lūn-bûn

@nan

2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Comparison of lumiracoxib with ...... s: randomised controlled trial

@ast

Comparison of lumiracoxib with ...... s: randomised controlled trial

@en

Comparison of lumiracoxib with ...... s: randomised controlled trial

@nl

type

label

Comparison of lumiracoxib with ...... s: randomised controlled trial

@ast

Comparison of lumiracoxib with ...... s: randomised controlled trial

@en

Comparison of lumiracoxib with ...... s: randomised controlled trial

@nl

prefLabel

Comparison of lumiracoxib with ...... s: randomised controlled trial

@ast

Comparison of lumiracoxib with ...... s: randomised controlled trial

@en

Comparison of lumiracoxib with ...... s: randomised controlled trial

@nl

P1433

Q28211411-9C663DA9-BF9D-4DAA-B553-141A7CD5C602

P1476

Q28211411-B23C6E31-E2F5-4762-8B11-79978B2961DE

P2093

Q28211411-1017DDDA-47CF-4598-B015-6D34C28D30F6

Q28211411-223FFEAB-181B-4AB0-A824-FAD534130FEC

Q28211411-2DDAB192-E13E-4837-BBED-3C6426785C04

Q28211411-4DADED23-1169-458A-AFD3-DE02F6D9651E

Q28211411-5A908141-0865-41EE-B9A9-9F7AE06BFF94

Q28211411-61EBFEC9-32D0-4E23-9E1D-95F10E928B54

Q28211411-91A4BDAE-324D-41AB-98B7-A5E9BEEF3EB6

Q28211411-A13B1D79-E436-4D7A-A35B-E0685EC39765

Q28211411-C1C951BF-2D53-4B52-AB31-31A501541287

Q28211411-C81F2592-F5AA-44A9-B7B8-3503E2F7AFDA

P304

Q28211411-7739832B-7E1D-4068-A057-5422372B655A

P31

Q28211411-2EFC6858-7BBA-4B17-85E5-5568073BA014

P356

Q28211411-17967748-A895-411C-A894-67060083CC02

P407

Q28211411-19DA1D52-430A-4E1F-8643-7DCB797F530F

P433

Q28211411-EF5D4752-4920-4C2A-B609-BEA643A02F46

P478

Q28211411-DC05470C-1A33-4622-9501-FCA7AFC74AB5

P50

Q28211411-9BA28A14-43BC-4460-85BE-CD9EFC688282

P577

Q28211411-493AA4FA-8816-41C6-A150-89B1F980EDEC

P698

Q28211411-6AAD2238-A264-4440-A42D-DF0E5A7B1325

P356

S0140-6736(04)16893-1

P1433

P1476

Comparison of lumiracoxib with ...... s: randomised controlled trial

@en

P2093

Alberto Gimona

http://www.w3.org/2001/XMLSchema#string

Bernhard Mellein

http://www.w3.org/2001/XMLSchema#string

Christopher J Hawkey

http://www.w3.org/2001/XMLSchema#string

Eduardo Mysler

http://www.w3.org/2001/XMLSchema#string

Elena Ehrsam

http://www.w3.org/2001/XMLSchema#string

Gerd R Burmester

http://www.w3.org/2001/XMLSchema#string

Gerhard Krammer

http://www.w3.org/2001/XMLSchema#string

Marc C Hochberg

http://www.w3.org/2001/XMLSchema#string

Patrice Matchaba

http://www.w3.org/2001/XMLSchema#string

Thomas J Schnitzer

http://www.w3.org/2001/XMLSchema#string

P304

665-74

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(04)16893-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

9435

http://www.w3.org/2001/XMLSchema#string

P478

364

http://www.w3.org/2001/XMLSchema#string

P50

Michael Doherty

P577

2004-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15325831

http://www.w3.org/2001/XMLSchema#string